Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 168 matching trials from the live ClinicalTrials.gov search.
Completed No phase listed Observational

Fibroid Growth Study

NCT00340288
Conditions
Uterine Leiomyomas
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years · Female only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Menorrhagia, Uterine Fibroids
Interventions
Doppler-Guided Uterine Artery Occlusion Device (DUAO)
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Southfield, Michigan + 6 more
Conditions
Fibroid Uterus, Gynecologic Disease, Leiomyoma, Uterine
Interventions
Carboprost Tromethamine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Uterine Fibroids
Interventions
Proellex, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 10 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Does 3D Laparoscopy Improve Vaginal Cuff Suture Time?

NCT02192606
Conditions
Uterine Fibroids, Abnormal Uterine Bleeding, Pelvic Pain, Adenomyosis
Interventions
Storz 3D Laparoscopy System, 2D Laparoscopy
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Post Market Evaluation of Acessa With TAG

NCT01842789
Conditions
Uterine Fibroids
Interventions
Acessa Procedure
Device
Lead sponsor
Acessa Health, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Ramon, California
Conditions
Contraception
Interventions
Relugolix Combination Therapy
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
109
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 89 more
Conditions
Uterine Fibroids, Uterine Leiomyomas
Interventions
ExAblate 2000
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
4
States / cities
La Jolla, California • Burlington, Massachusetts • Kalamazoo, Michigan + 1 more
Completed Not applicable Interventional Results available

Sonography Guided Transcervical Ablation of Uterine Fibroids

NCT02228174
Conditions
Menorrhagia
Interventions
Intrauterine Ultrasound-Guided Radiofreq. Ablation System
Device
Lead sponsor
Gynesonics
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
22
States / cities
Phoenix, Arizona • Denver, Colorado • Newark, Delaware + 19 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Combined Vaginal Misoprostol and Perivascular Vasopressin

NCT03815344
Conditions
Leiomyoma, Laparoscopy, Uterine Myomectomy
Interventions
Standard, Standard-vaginal misoprostol
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors, Benign Prostatic Hyperplasia
Interventions
Treatment with HydroPearl via radial access
Device
Lead sponsor
Terumo Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 3 more
Completed Not applicable Interventional Results available

MyoSure Hysteroscopic Tissue Removal System Registry Study

NCT01369758
Conditions
Uterine Fibroids, Polyps
Interventions
MyoSure Tissue Removal System
Device
Lead sponsor
Hologic, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Marlborough, Massachusetts
Conditions
Fibroid Uterus
Interventions
Bupivacaine, Bupivacaine liposome, normal saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial of Mifepristone for Fibroids

NCT00133705
Conditions
Leiomyoma
Interventions
Mifepristone, Inert Capsule
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
Rochester, New York
Conditions
Uterine Fibroids
Interventions
Vilaprisan (BAY1002670), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
46
States / cities
Canyon Country, California • Encinitas, California • Huntington Park, California + 35 more
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Vilaprisan in Renal Impairment

NCT03411980
Conditions
Uterine Fibroids, Endometriosis
Interventions
Vilaprisan (BAY1002670)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Recruiting No phase listed Observational Accepts healthy volunteers

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

NCT00005095
Conditions
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Ovarian Cancer, Sarcoma, Uterine Leiomyomata, Vaginal Cancer, Vulvar Cancer
Interventions
Ca-125, screening questionnaire administration, Surgery
Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2040
U.S. locations
1
States / cities
Chicago, Illinois
Completed No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Elastography (MRE) of Uterine Fibroids

NCT01229826
Conditions
Uterine Fibroids
Interventions
MR Elastography
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Not applicable Interventional Results available

Symphion® System In-Office Study

NCT02520414
Conditions
Uterine Leiomyomas, Endometrial Polyps
Interventions
Symphion® Bipolar Hysteroscopic Tissue Resection System
Device
Lead sponsor
Minerva Surgical, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Uterine Fibroids, Endometriosis
Interventions
Relugolix Combination Tablet
Drug
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
120
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more
Conditions
Uterine Fibroid, Endometriosis
Interventions
Not listed
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
660 participants
Timeline
2018 – 2020
U.S. locations
37
States / cities
Mobile, Alabama • Mesa, Arizona • Huntington Beach, California + 31 more
Terminated Not applicable Interventional Accepts healthy volunteers

Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization

NCT06106633
Conditions
Uterine Bleeding, Uterine Fibroid
Interventions
TriNaV
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Completed Not applicable Interventional

Post Market TRUST - U.S.A. Study

NCT02163525
Conditions
Symptomatic Uterine Fibroids
Interventions
Global Fibroid Ablation (GFA), Abdominal or Laparoscopic Myomectomy, Uterine Artery Embolization (UAE)
Procedure
Lead sponsor
Acessa Health, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
9
States / cities
Santa Monica, California • Walnut Creek, California • Augusta, Georgia + 6 more
Conditions
Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Metastatic Renal Cell Carcinoma, Skin Leiomyoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Uterine Corpus Leiomyoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Mercaptopurine, Questionnaire Administration, Skin Biopsy
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Los Angeles, California